
Keros Therapeutics Inc
NASDAQ:KROS

Intrinsic Value
The intrinsic value of one
KROS
stock under the Base Case scenario is
3.16
USD.
Compared to the current market price of 14.3 USD,
Keros Therapeutics Inc
is
Overvalued by 78%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Keros Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Keros Therapeutics Inc
Balance Sheet Decomposition
Keros Therapeutics Inc
Current Assets | 588.9m |
Cash & Short-Term Investments | 559.9m |
Receivables | 2.7m |
Other Current Assets | 26.2m |
Non-Current Assets | 27m |
PP&E | 23.5m |
Other Non-Current Assets | 3.5m |
Free Cash Flow Analysis
Keros Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Keros Therapeutics Inc
Revenue
|
3.6m
USD
|
Operating Expenses
|
-214.4m
USD
|
Operating Income
|
-210.8m
USD
|
Other Expenses
|
23.5m
USD
|
Net Income
|
-187.4m
USD
|
KROS Profitability Score
Profitability Due Diligence
Keros Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Score
Keros Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
KROS Solvency Score
Solvency Due Diligence
Keros Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Keros Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KROS Price Targets Summary
Keros Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
KROS
is 31.62 USD
with a low forecast of 15.15 USD and a high forecast of 45.15 USD.
Dividends
Current shareholder yield for KROS is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
KROS
stock under the Base Case scenario is
3.16
USD.
Compared to the current market price of 14.3 USD,
Keros Therapeutics Inc
is
Overvalued by 78%.